Clostridium Patents (Class 435/252.7)
  • Patent number: 10640792
    Abstract: Controlling the gas inlet flow rate and energy input to a fermentation reactor to maximize conversion of syngas by maximizing uptake of hydrogen into a medium relative to carbon dioxide and carbon monoxide based on determined volumetric mass transfer coefficients for hydrogen, carbon monoxide, and carbon dioxide.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: May 5, 2020
    Assignee: The Board of Regents for Oklahoma State University
    Inventors: Hasan K. Atiyeh, John Randall Phillips, Raymond L. Huhnke
  • Patent number: 10100337
    Abstract: A process provides high ethanol productivity levels during fermentation of a CO-containing substrate. The process controls CO-substrate feed rates and cell density to avoid culture upset and CO inhibition. The process includes fermenting a CO-containing gaseous substrate to obtain a target cell density and a target CO feed rate, and then periodically reducing and increasing the CO feed rate.
    Type: Grant
    Filed: February 9, 2014
    Date of Patent: October 16, 2018
    Inventors: Peter Simpson Bell, Song Liu
  • Patent number: 9885063
    Abstract: A process is provided for fermenting CO-containing gaseous substrates in a low phosphate medium. The process includes blending a liquid medium that includes at least one transition metal element with a liquid medium that includes at least at least one other transition metal element and one non-metal element to provide a fermentation medium. The process is effective for preventing precipitation of one or more transition metal elements with one or more non-metal elements. The fermentation medium used in the process is prepared in a way that requires significantly lower amounts of water and reduced levels of phosphate.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: February 6, 2018
    Inventors: Ryan H. Senaratne, Peter Simpson Bell, Song Liu, Syrona R. Scott
  • Patent number: 9598685
    Abstract: Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; SI 20 IV; or combinations thereof. Specific combination mutations include E1 191M and S1199L, E1191M and S1199Y, E1191M and S1199F, E1191Q and S1199L, E1191Q and S 1199Y, or E 1191 Q and S 1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: March 21, 2017
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Min Dong, Lisheng Peng, Pål Erik Gustav Stenmark, Ronnie Per Arne Berntsson
  • Patent number: 9217172
    Abstract: The present invention relates to compositions and methods for testing agents (e.g., Clostridium botulinum neurotoxin (BoNT) detection and analysis). In particular, the present invention relates to the use of Human induced pluripotent stem (hiPS) derived cells for agent detection and analysis.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: December 22, 2015
    Assignee: CELLSNAP, LLC
    Inventors: Eric Arthur Johnson, Sabine Pellett, William Howard Tepp, Regina Clare Meyer Whitemarsh
  • Patent number: 9115347
    Abstract: The invention provides methods and compositions (such as for example, culture media) for culturing Clostridium difficile and producing the C. difficile Toxins A and B.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: August 25, 2015
    Assignee: Sanofi Pasteur Biologies, LLC
    Inventors: Aiqi Fang, Andrew James White, Seshu Tummala, Lee Wilson
  • Publication number: 20150147313
    Abstract: The present invention refers to a culture medium and a process for producing proteases with collagenolytic and gelatinolytic activity by bacteria of the genus Clostridium. Particularly, the present invention refers to an animal product-free culture medium for C. histolyticum, characterized by comprising non-animal origin peptones, preferably vegetable peptones, yeast extract and the amino acids cysteine and arginine. The present invention also refers to a process for producing Clostridium histolyticum liquid culture supernatant comprising one or more proteases with collagenolytic and gelatinolytic activity, and pharmaceutical composition comprising as active ingredient the supernatant or the supernatant optionality purified.
    Type: Application
    Filed: May 29, 2013
    Publication date: May 28, 2015
    Inventors: Marcos Castanheira Alegria, Lucidio Cristoväo Fardelone, Marina Baiochi Riboldi Delalana, Josef Ernst Thiemann, Spartaco Astolfi Filho, Roberto Carlos Debom Moreira, Ogari de Castro Pacheco
  • Publication number: 20150147315
    Abstract: The present invention relates to a derivative bacterial strain of an avirulent, non-pathogenic Clostridium ghonii that is capable of arresting the growth of, regressing or destroying one or more solid tumours. The present invention further relates to a composition comprising the derivative bacterial strain for targeted lysis of solid tumours. The present invention further relates to methods of producing derivative strains of C. ghonii by serial culturing in tumor bearing animals.
    Type: Application
    Filed: April 29, 2013
    Publication date: May 28, 2015
    Inventor: Ming Wei
  • Publication number: 20150143557
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Application
    Filed: September 22, 2014
    Publication date: May 21, 2015
    Inventors: KENYA HONDA, KOJI ATARASHI, KIKUJI ITOH, TAKESHI TANOUE
  • Publication number: 20150140550
    Abstract: Methods for aiding in the diagnosis of disorders including, but not limited to, PDDs (Pervasive Development Disorders), Dysautonomic disorders, Parkinson's disease and SIDS (Sudden Infant Death Syndrome). In one aspect, a diagnosis method comprises analyzing a stool sample of an individual for the presence of a biological marker (or marker compound) comprising one or more pathogens, which provides an indication of whether the invidual has, or can develop, a disorder including, but not limited to, a PDD, Dysautonomia, Parkinsons disease and SIDS. Preferably, the presence of one or more pathogens is determined using a stool immunoassay to determine the presence of antigens in a stool sample, wherein such antigens are associated with one or more pathogens including, but not limited to, Giardia, Cryptosporidium, E. histolytica, C. difficile, Adenovirus, Rotavirus or H. pylori.
    Type: Application
    Filed: October 30, 2014
    Publication date: May 21, 2015
    Inventor: Joan M. Fallon
  • Patent number: 9034618
    Abstract: The present invention relates to methods for sustaining microorganism culture in a syngas fermentation reactor in decreased concentration or absence of various substrates comprising: adding carbon dioxide and optionally alcohol; maintaining free acetic acid concentrations; and performing the above mentioned steps within specified time.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: May 19, 2015
    Assignee: INEOS BIO SA
    Inventors: Stephen S. Adams, Syrona Scott, Ching-Whan Ko
  • Publication number: 20150132740
    Abstract: A concentration agent for microorganisms is provided that contains both lanthanum and carbonate. Additionally, articles that include the concentration agent and methods of concentrating a microorganism using the concentration agent are provided.
    Type: Application
    Filed: May 23, 2013
    Publication date: May 14, 2015
    Inventors: Manjiri T. Kshirsagar, Evan Koon Lun Yuuji Hajime, Andrew W. Rabins
  • Patent number: 9028841
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: May 12, 2015
    Assignee: Seres Health, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David A. Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Publication number: 20150104423
    Abstract: The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 16, 2015
    Applicant: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Pirjo WACKLIN, Jaana MATTO, Harri MAKIVUOKKO, Jukka PARTANEN, Janne NIKKILA
  • Publication number: 20150098888
    Abstract: The invention provides a process for producing ammonia or ammonium from an organic material, the method by contacting the organic material with at least one hydrolytic enzyme, in a medium, to produce a medium including hydrolyzed or partially hydrolyzed organic material suitable for microbial fermentation. The hydrolyzed or partially hydrolyzed medium with organic material is then fermented in the presence of at least one microorganism capable of ammonification, wherein the fermenting is under conditions, and for a sufficient period of time, to produce a fermentation product that comprises ammonia or ammonium. The organic material includes nitrogenous compounds suitable for conversion to ammonia or ammonium.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 9, 2015
    Inventors: Veikko LATVALA, Ari KETOLA, Ilona OSKANEN, Kerttu KOSKENNIEMI, Maiju LAAKSONEN, Elisa LENSU
  • Publication number: 20150093796
    Abstract: The present invention provides Clostridium acetobutylicum and an application thereof. A preservation number of the Clostridium acetobutylicum provided in the invention is CGMCC No. 5234. The Clostridium acetobutylicum provided in the present invention can be used for cogeneration of acetone, butanol, ethanol, and 3-hydroxy butanone through fermentation, so as to improve the economic benefit of butanol fermentation. NAD+ coupling and regeneration can be implemented by adding metabolism or growth regulating substances, so as to improve the product yield, and at the same time, the yield of cogeneration products can be flexibly adjusted, so as to cater for the market demand.
    Type: Application
    Filed: March 20, 2012
    Publication date: April 2, 2015
    Inventors: Hanjie Ying, Dong Liu, Yong Chen, Yong Chen, An Li, Tao Zhou, Jinglan Wu, Xiaoqing Lin, Xiaochun Chen, Jingjing Xie, Jianxin Bai
  • Publication number: 20150087614
    Abstract: Provided herein are methods for inducing cell death in a gram positive bacterium and methods for reducing the proliferation of a gram positive bacterium that include contacting a gram positive bacterium with a dye (e.g., an azo dye) and a TarO inhibitor. Also provided are methods of treating a subject having a gram positive bacterial infection that include administering to a subject having a gram positive bacterial infection a dye (e.g., an azo dye) and a TarO inhibitor. Also provided are compositions containing a dye (e.g., an azo dye) and a TarO inhibitor, and kits containing at least one of these compositions.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 26, 2015
    Inventors: Michael S. Gilmore, Takashi Suzuki
  • Patent number: 8968747
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
  • Publication number: 20150044743
    Abstract: Method of cell culture, comprising adding a redox active compound with a redox potential of between ?0.116 to ?0.253 to a culture capable of forming hydrogen via a hydrogenase so that the redox potential is diverted from hydrogen to form a longer chain acids, e.g., butryic acid.
    Type: Application
    Filed: December 20, 2012
    Publication date: February 12, 2015
    Inventors: George N. Bennett, Xianpeng Cai
  • Patent number: 8936790
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: January 20, 2015
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
  • Patent number: 8906668
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: December 9, 2014
    Assignee: Seres Health, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David A. Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Publication number: 20140341921
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: November 29, 2012
    Publication date: November 20, 2014
    Applicants: The University of Tokyo, School Corporation , Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20140335623
    Abstract: The present invention relates to methods and compositions for engineering sporulating bacterial cells, particularly a cell of the class Clostridia. In particular, the present invention relates to the generation of sporulation deficient bacteria for the generation of industrial superior phenotypes.
    Type: Application
    Filed: May 9, 2014
    Publication date: November 13, 2014
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Bryan P. Tracy, Carlos J. Paredes, Eleftherios T. Papoutsakis
  • Patent number: 8852918
    Abstract: A biologically pure isolate of a selected bacterium derived from Clostridium autoethanogenum is described which has improved efficiency in the production of ethanol by anaerobic fermentation of substrates comprising carbon monoxide. The bacterium can produce ethanol and acetate at an ethanol to acetate ratio of at least 1.0 and has a productivity of at least 1.2 g of ethanol/l of fermentation broth per day. The bacterium is also characterized in that it has substantially no ability to sporulate.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: October 7, 2014
    Assignee: Lanzatech New Zealand Limited
    Inventors: Sean Dennis Simpson, Richard Llewellyn Sydney Forster, Phuong Loan Tran, Matthew James Rowe, Ian Linstrand Warner
  • Patent number: 8852600
    Abstract: In one aspect, the invention provides a DNA molecule. The DNA molecule includes a nucleotide sequence that encodes the receptor-binding domain of Clostridium difficile toxin A or toxin B in which at least about 10% of the in-frame codons for each amino acid residue has a higher percentage use in the human genome than the corresponding in-frame codons of C. difficile toxin A or toxin B having a known sequence. Methods for generating antibodies to Clostridium difficile toxin A or toxin B, methods for reducing the risk of a C. difficile infection, and methods for treating a C. difficile are also provided.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: October 7, 2014
    Assignees: The Rockefeller University, Cornell University
    Inventors: David F. Gardiner, Yaoxing Huang
  • Publication number: 20140273120
    Abstract: This invention provides methods and systems for the production of propanol. Specifically, the methods and systems of the present invention use symbiotic co-cultures for the production of propanol from syngas.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventors: Rathin Datta, Michael Enzien, Robert Hickey, William Levinson
  • Publication number: 20140242654
    Abstract: A clostridia bacterial species Clostridium pharus, is provided. Under anaerobic conditions Clostridium pharus can convert ethanol and/or acetate to butyric acid.
    Type: Application
    Filed: February 26, 2013
    Publication date: August 28, 2014
    Applicant: COSKATA, INC.
    Inventor: William E. Levinson
  • Patent number: 8802405
    Abstract: An isolated clostridia bacterial species (Clostridium coskatii ATCC No. PTA-10522, “PS02”) is provided. Under anaerobic conditions C. coskatii can convert CO and/or H2 and/or CO2 to ethanol or acetate. Thus, this bacterium is capable of transforming waste gases (e.g. syngas and refinery wastes) into useful products.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: August 12, 2014
    Assignee: Coskata, Inc.
    Inventors: James A. Zahn, Jyotisna Saxena
  • Publication number: 20140206052
    Abstract: This invention provides methods and systems for the production of butanol. Specifically, the methods and systems of the present invention use syntrophic co-cultures for the production of butanol from syngas.
    Type: Application
    Filed: January 18, 2013
    Publication date: July 24, 2014
    Applicant: Coskata, Inc.
    Inventors: Mike Enzien, Rathin Datta, Richard Tobey
  • Publication number: 20140206066
    Abstract: This invention provides compositions for the production of butanol. Specifically, the compositions of the present invention use syntrophic co-cultures for the production of butanol from syngas.
    Type: Application
    Filed: January 18, 2013
    Publication date: July 24, 2014
    Applicant: COSKATA, INC.
    Inventors: Rathin Datta, Andrew Reeves
  • Patent number: 8765399
    Abstract: Disclosed are culture media, protocols and kits for diagnosis of toxigenic Clostridium difficile, where the culture medium comprises Cooked Meat Medium with glucose; yeast extract; taurocholate; cycloserine; and cefoxitin.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: July 1, 2014
    Assignee: Montefiore Medical Center
    Inventor: Paul Riska
  • Publication number: 20140170637
    Abstract: Methods for aiding in the diagnosis of disorders including, but not limited to, PDDs (Pervasive Development Disorders), Dysautonomic disorders, Parkinson's disease and SIDS (Sudden Infant Death Syndrome). In one aspect, a diagnosis method comprises analyzing a stool sample of an individual for the presence of a biological marker (or marker compound) comprising one or more pathogens, which provides an indication of whether the individual has, or can develop, a disorder including, but not limited to, a PDD, Dysautonomia, Parkinsons disease and SIDS. Preferably, the presence of one or more pathogens is determined using a stool immunoassay to determine the presence of antigens in a stool sample, wherein such antigens are associated with one or more pathogens including, but not limited to, Giardia, Cryptosporidium, E. histolytica, C. difficile, Adenovirus, Rotavirus or H. pylori.
    Type: Application
    Filed: September 26, 2013
    Publication date: June 19, 2014
    Applicant: Curemark, LLC
    Inventor: Joan M. Fallon
  • Publication number: 20140147873
    Abstract: In various embodiments a system is provided that displays heterologous proteins on the surface of a Gram-positive microorganism. In certain embodiments the system displays proteins using a sortase transpeptidase to covalently anchor proteins to the cell wall of the microbe. Novel bacterial strains are provided to exploit this system to display cellulase enzymes and multi-enzyme complexes on the surface of Gram-positive microorganisms (e.g., Bacillus subtilis) through their non-covalent interaction with a scaffoldin protein that is covalently anchored to the cell wall by the sortase transpeptidase. The surface displayed protein complexes contain enzymes capable of degrading cellulose into its component sugars at accelerated rates as compared to solutions of purified enzymes.
    Type: Application
    Filed: February 29, 2012
    Publication date: May 29, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Robert T. Clubb, Timothy Anderson
  • Patent number: 8735133
    Abstract: Described herein are molecules, constructs and methods for the production and secretion of polypeptides of interest by host cells, preferably bacterial host cells, and more particularly gram positive bacteria. In particular, the present invention is related to a polynucleic acid encoding a fusion protein and to uses thereof for the secretion of heterologous or homologous polypeptides of interest by a bacterial host cell, preferably Clostridium bacteria. The present invention further relates to methods and constructs for the production and secretion of heterologous or homologous polypeptides of interest proteins by host cells using such polynucleic acids and fusion proteins.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: May 27, 2014
    Inventors: Henri-Pierre Fierobe, Florence Mingardon, Angélique Chanal-Vial
  • Publication number: 20140120591
    Abstract: An isolated biologically pure culture of Clostridium tyrobutyricum ITRI04001 or an isolated biologically pure culture of Clostridium tyrobutyricum having the genotypic characteristics of ITRI04001 useful for syngas fermentation. Volatile free acids are produced by a method comprising culturing a microorganism having the genotypic characteristics of ITRI04001 in a medium; providing at least one substrate comprising at least one carbon source chosen from CO and CO2 to the microorganism; and recovering at least one free volatile free acid. Syngas can be the at least one substrate in these processes for producing volatile free acids.
    Type: Application
    Filed: October 2, 2013
    Publication date: May 1, 2014
    Applicant: Industrial Technology Research Institute
    Inventors: Chang-Chieh Chen, Yi-Te Chou, Shao-Wen Wu, Shi-Chan Tseng, Hsin-Tzu Kuo, Wan-Ting Ma
  • Publication number: 20140083933
    Abstract: The present invention relates to a method in which a microbial fuel cell (MFC) is used in order to produce electrical power while also either eliminating heavy metals or recovering precious metals from wastewater containing the heavy metals or the precious metals, and, more particularly, the invention has advantages including effective elimination of Hg2+ or any other heavy metals in the form of a solid precipitate or deposit of Hg or Hg2Cl2 or any other such deposits or effective recovery of Ag or any other precious metals in the form of solid precipitates or deposits, and incidentally, power is produced, by-products are rendered harmless and long-term economic operation is achieved.
    Type: Application
    Filed: July 13, 2011
    Publication date: March 27, 2014
    Inventors: CHANSOO CHOI, MIKE YOUNG SHIN
  • Patent number: 8673291
    Abstract: This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically kill Clostridium difficile bacteria, dangerous human pathogens. Also disclosed are methods of producing the R-type bacteriocins in innocuous producer cells that, unlike C. difficile, do not die in the presence of oxygen. Disclosed also is the specific gene of the isolated gene cluster that determines the killing spectrum of the R-type bacteriocin and the demonstration that the killing spectra of diffocins can be altered by engineering orf1374 of the diffocin genetic locus. This invention offers a potent bactericidal agent and a means to make it in order to kill selectively C. difficile bacteria in the environment of the gastrointestinal tract where they can cause great harm and even death of the infected patient or farm animal.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: March 18, 2014
    Assignee: AvidBiotics Corp.
    Inventors: Dean M. Scholl, Dana M. Gebhart, Steven R. Williams, Gregory R. Govoni, David W. Martin, Jr.
  • Patent number: 8669082
    Abstract: The present invention relates to the production of biofuels by utilizing efficient biomass digestion and fermentation by a new thermophilic microorganism generated after fusion of two different bacteria Clostridium thermocellum and C. acetobutylicum and properly mutating the fused bacteria to produce biofuels and other economically important chemicals in a single vessel from lignocellulosic derived renewable biomass. All the necessary biochemical digestions and fermentation are carried out by this single thermophilic microorganism in one single vessel eliminating the need for multiple step digestion and fermentation processes, requiring multiple chambers. It also significantly reduces the rate limiting steps where increasing accumulation of alcohol, butanol and other substances become toxic to the very bacteria that produce these biofuels. The single vessel is incubated at high temperatures (45° C. or above) to eliminate the need for periodic stoppage and restarting of the process.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: March 11, 2014
    Assignee: Claflin University
    Inventors: Omar Bagasra, Kamal Chowdhury, Verlie A. Tisdal, George E. Miller, III, Rebecca Bullard-Dillard
  • Patent number: 8669085
    Abstract: The present invention provides a sonoporation-based method that can be universally applied for delivery of compounds into Gram positive bacteria. Gram positive bacteria which can be transformed by sonoporation include, for example, Bacillus, Streptococcus, Acetobacterium, and Clostridium. Compounds which can be delivered into Gram positive bacteria via sonoporation include nucleic acids (DNA or RNA), proteins, lipids, carbohydrates, viruses, small organic and inorganic molecules, and nano-particles.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: March 11, 2014
    Assignee: UT-Battelle, LLC
    Inventors: Yunfeng Yang, Yongchao Li
  • Publication number: 20140045246
    Abstract: A process for fermenting syngas is provided which is effective for decreasing an amount of time needed to inoculate a main reactor. The process includes propagating a culture of acetogenic bacteria to provide an incoulum for a main reactor and fermenting syngas in the main reactor.
    Type: Application
    Filed: October 22, 2013
    Publication date: February 13, 2014
    Applicant: INEOS BIO SA
    Inventors: Peter Simpson Bell, Ching-Whan Ko
  • Publication number: 20140017767
    Abstract: The present invention relates to microbial inocula and in particular to standardised inocula for producing reference cultures of microorganisms. The invention has been developed primarily for use as a solid, disc-shaped, inoculum and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
    Type: Application
    Filed: June 21, 2013
    Publication date: January 16, 2014
    Applicant: AMS Laboratories Pty Ltd
    Inventors: Paul PRISCOTT, Yi-hong WANG
  • Patent number: 8617569
    Abstract: A method for treating a patient with migraine headache includes administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form. The administration includes extramuscular injection of the neurotoxin to emerging nerve points including foraminal sites for enabling neurotoxin access to concentrated nerve bundles at exit points of the foramina.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: December 31, 2013
    Inventor: William J. Binder
  • Publication number: 20130344555
    Abstract: The present invention relates to a novel anaerobic, extreme thermophilic, ethanol high-yielding bacterium. The invention is based on the isolation of the bacterial strain referred to herein as “DTU01”, which produces ethanol as the main fermentation product, followed by acetate and lactate. The isolated organism is an extremely interesting and very promising organism for the establishment of a sustainable bioethanol production process. The invention further relates to a method for producing a fermentation product such as ethanol.
    Type: Application
    Filed: November 1, 2011
    Publication date: December 26, 2013
    Applicant: TECHNICAL UNIVERSITY OF DENMARK
    Inventors: Irini Angelidaki, Ana F. Tomás, Dimitar Borisov Karakashev
  • Patent number: 8613917
    Abstract: Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: December 24, 2013
    Assignee: The Johns Hopkins University
    Inventors: Long Dang, Chetan Bettegowda, Kenneth W. Kinzler, Bert Vogelstein
  • Patent number: 8597639
    Abstract: The present invention provides an adjunctive agent and a method for lavaging the alimentary canal, which is able to reduce a dose of oral cleaning agent for lavaging the alimentary canal and is capable of realizing an excellent cleaning effect at the time of use of the oral cleaning agent. The adjunctive agent comprises butyric acid bacterium (for example, Clostridium butyricum and the like) and/or lactic acid bacterium (for example, species belonging to the genus Lactobacillus and the genus Bifidobacterium).
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: December 3, 2013
    Assignee: Miyarisan Pharmaceutical Co., Ltd.
    Inventors: Shinji Kumagai, Mamoru Tanaka
  • Publication number: 20130316422
    Abstract: A process is provided for fermentation of syngas that is effective for reducing conductivity and providing an alcohol STY of about 10 g ethanol/(L·day). The process includes introducing the syngas into a reactor vessel and providing a nitrogen feed rate to the reactor vessel of about 100 mg or more nitrogen/gram of cells produced. Fermentation of the syngas is effective for providing a fermentation medium having an average conductivity of about 16 mS/cm or less and an STY of 10 g ethanol/(L·day) or more.
    Type: Application
    Filed: May 9, 2013
    Publication date: November 28, 2013
    Applicant: INEOS BIO S.A.
    Inventors: Syrona Scott, Song Liu, Ching-Whan Ko
  • Publication number: 20130316420
    Abstract: A process for fermenting syngas and a fermentation medium provides high ethanol productivity while removing medium components that were previously thought to be essential. The process is effective for providing a specific STY of at least about 1 g ethanol/(L·day·gram cells). In this aspect, the fermentation medium has less than about 1.04 ppm boron, less than about 0.16 ppm manganese, less than about 0.26 ppm molybdenum, or less than about 0.16 ppm copper.
    Type: Application
    Filed: May 8, 2013
    Publication date: November 28, 2013
    Inventors: Syrona Scott, Ryan Senaratne, Ching-Whan Ko
  • Publication number: 20130316421
    Abstract: A process for fermenting syngas and a fermentation medium provides high ethanol productivity while removing medium components that were previously thought to be essential. The process is effective for providing a specific STY of at least about 1 g ethanol/(L·day·gram cells). In this aspect, the fermentation medium has a weight ratio of NH4+ to B of about 625:1 or more, or a weight ratio of NH4+ to Mn of about 4050:1 or more, or a weight ratio of NH4+ to Mo of about 2500:1 or more, or a ratio of NH4+ to Cu of about 4050:1 or more; or the fermentation medium has a weight ratio of P to B of about 30:1 or more, or a weight ratio of P to Mn of about 190:1 or more, or a weight ratio of P to Mo of about 120:1 or more, or a weight ratio of Mn to Cu of about 190:1 or more; or the fermentation medium has a weight ratio of K to B of about 35:1 or more, or a weight ratio of K to Mn of about 245:1 or more, or a weight ratio of K to Mo of about 150:1 or more, or a weight ratio of K to Cu of about 245:1 or more.
    Type: Application
    Filed: May 9, 2013
    Publication date: November 28, 2013
    Applicant: INEOS BIO S.A.
    Inventors: Syrona Scott, Ryan Senaratne, Ching-Whan Ko
  • Patent number: 8592191
    Abstract: A process for fermenting syngas is provided which is effective for decreasing an amount of time needed to inoculate a main reactor. The process includes propagating a culture of acetogenic bacteria to provide an inoculum for a main reactor and fermenting syngas in the main reactor.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: November 26, 2013
    Assignee: INEOS Bio SA
    Inventors: Peter Simpson Bell, Ching-Whan Ko
  • Publication number: 20130288340
    Abstract: An object of the present invention is to provide a microorganism which is novel at the elemental composition level, and to provide a technique for providing such a microorganism. The present inventor has succeeded in causing a microorganism to efficiently contain a non-essential element by decreasing the content of an essential nutrient source for the microorganism, a C source, an N source, a P source, or an S source, and by adding an X compound containing the non-essential element as a constitutive element in a manner to make up for the decreased amount, and then culturing the microorganism.
    Type: Application
    Filed: September 5, 2011
    Publication date: October 31, 2013
    Applicants: PARA MICROBIOS LABORATORIES LLC
    Inventor: Yoshitake Tanaka